Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP

Tonix Pharmaceuticals — Investor Presentation (October 2018)

37 slides from Tonix Pharmaceuticals's investor presentation, Oct 2, 2018

  1. Slide 1: Investor Presentation October 2018

    © 2018 Tonix Pharmaceuticals Holding Corp. October 2018 Version P0139 10 - 1 - 18 (Doc 0400) Investor Presentation

  2. Slide 2: Cautionary Note on Forward-Looking Statements

    © 2018 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat

  3. Slide 3: Tonix Development Highlights

    © 2018 Tonix Pharmaceuticals Holding Corp. 3 Lead Program Tonmya ®1 – FDA Breakthrough Therapy in PTSD 2 – Bedtime treatment in Phase 3 Development • Results from 2 efficacy studies can improve a new Phase 3 study design • FDA feedback and agreement are expected 4Q2018 • Pivotal efficacy study may i

  4. Slide 4: Candidates in Development

    © 2018 Tonix Pharmaceuticals Holding Corp. 4 Candidates in Development Preclinical Phase 2 NDA 1 /BLA 2 Market Pipeline Product Indication/ Description Phase 3 Tonmya Bedtime Treatment for PTSD Daytime Treatment for PTSD TNX - 601 Novel polymorph and salt discovered and characterized; Preliminary hu

  5. Slide 5: Tonmya for PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 5 Tonmya for PTSD Breakthrough Therapy (BT) designation from the FDA • Expedited development and accelerated approval are expected One Phase 2 study completed and one Phase 3 study stopped early due to inadequate separation from placebo (unblinded interim a

  6. Slide 6: Breakthrough Therapy Designation

    © 2018 Tonix Pharmaceuticals Holding Corp. 6 Breakthrough Therapy Designation FDA granted Tonmya Breakthrough Therapy designation – reported December 19, 2016 • PTSD is a serious condition • Tonmya has potential advantages over existing therapies in military - related PTSD Benefits of Breakthrough T

  7. Slide 7: No Recognized Abuse Potential in Clinical Studies

    © 2018 Tonix Pharmaceuticals Holding Corp. 7 No Recognized Abuse Potential in Clinical Studies Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants • Cyclobenzaprine interacts with receptors that regulate sleep quality: 5 - HT 2A, a 1 - adrenergic and hist

  8. Slide 8: TNX-102 SL Intellectual Property – U.S. Protection until 2034

    © 2018 Tonix Pharmaceuticals Holding Corp. 8 TNX - 102 SL Intellectual Property – U.S. Protection until 2034 Composition of matter (eutectic) : Protection expected to 2034 • United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 9,636,408 in May 2017 and U.S. Patent No. 9,956,188 i

  9. Slide 9: TNX-102 SL: Sublingual Formulation Designed for Bedtime Administration

    © 2018 Tonix Pharmaceuticals Holding Corp. 9 TNX - 102 SL: Sublingual Formulation is Designed for Bedtime Administration TNX - 102 SL: Proprietary sublingual formulation of cyclobenzaprine (CBP) with transmucosal absorption • Innovation by design with patent protected CBP/mannitol eutectic • Rapid s

  10. Slide 10: Tonmya: Novel Mechanism Targets Sleep Quality for Recovery from PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 10 Tonmya: Novel Mechanism Targets Sleep Quality for Recovery from PTSD PTSD is a disorder of recovery • Most people exposed to extreme trauma recover over a few weeks • In PTSD, recovery process impeded due to insufficient sleep - dependent memory processi

  11. Slide 11: PTSD: Not Well-Served by Approved Treatments

    © 2018 Tonix Pharmaceuticals Holding Corp. 11 PTSD: Not Well - Served by Approved Treatments FDA - approved SSRIs, paroxetine and sertraline, are indicated as a treatment for PTSD • Neither drug has shown efficacy in military - related PTSD • Majority of male PTSD patients unresponsive or intolerant

  12. Slide 12: High Prevalence of PTSD Among Combat Veterans

    © 2018 Tonix Pharmaceuticals Holding Corp. 12 High Prevalence of PTSD Among Combat Veterans 1 Goldstein et al., 2016 ; 2 Norris, PTSD Res Quar . 2013; 3 Analysis of VA Health Care Utilization among Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn Veterans, from 1st Qtr FY

  13. Slide 13: AtEase/P201 Study in Military-Related PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 13 Phase 2 AtEase/P201 1 Study in Military - Related PTSD • Randomized, double - blind, placebo - controlled trial in military - related PTSD • Efficacy analysis from 231 * patients; 24 U.S. clinical sites • Enrolled patients with baseline CAPS - 5 2 ≥ 29 •

  14. Slide 14: AtEase/P201 Study Results

    © 2018 Tonix Pharmaceuticals Holding Corp. 14 AtEase/P201 Study AtEase was a large adequate well - controlled Phase 2 study in military - related PTSD • Primary endpoint (Week 12 CAPS - 5) did not separate from placebo for TNX - 102 SL 2.8 mg • No safety or tolerability issue discovered • Retrospect

  15. Slide 15: HONOR/P301 Study – Discontinued Due to High Placebo Response

    © 2018 Tonix Pharmaceuticals Holding Corp. 15 HONOR/P301 1 Study – Evidence of Efficacy at Week 4 Discontinued Due to High Placebo Response at Week 12 Primary e ndpoint CAPS - 5 2 : • Mean change from baseline at W eek 12 (Tonmya 5.6 mg vs. placebo ) Unblinded interim analysis at 274 randomized part

  16. Slide 16: HONOR/P301 Study Stopped After Interim Analysis

    © 2018 Tonix Pharmaceuticals Holding Corp. 16 HONOR/P301 Study Stopped After Interim Analysis (July 2018) HONOR was a large adequate well - controlled Phase 3 study in military - related PTSD • Separation on primary endpoint at Week 12 did not cross pre - specified study continuation threshold at We

  17. Slide 17: Retrospective Comparison of Time Since Trauma in P201 versus P301

    © 2018 Tonix Pharmaceuticals Holding Corp. 17 Retrospective Comparison of Time Since Trauma in AtEase/P201 versus HONOR/P301 (Tonmya 5.6 mg Groups) P301 study was initiated approximately two years later than Phase 2 P201 • The median time since trauma in Phase 3 was 9.5 years compared to the median

  18. Slide 18: Primary Outcome (CAPS-5) in Phase 3 and Time Since Trauma Subgroups

    © 2018 Tonix Pharmaceuticals Holding Corp. Primary Outcome (CAPS - 5) in Phase 3 ( mITT ) and ≤9 Years and >9 Years Time Since Trauma (TST) Subgroups P301 modified intent to treat ( mITT ) population * p=0.020, TNX - 102 SL 5.6 mg group v. placebo, using mixed model repeated measures (MMRM) P301 TST

  19. Slide 19: PTSD Treatment Response to Tonmya in Phase 2 and Phase 3 Studies

    © 2018 Tonix Pharmaceuticals Holding Corp. P201 Baseline CAPS - 5 ≥33 (majority TST 1 ≤9 yr ) *p<0.05, TNX - 102 SL 5.6 mg group v. placebo, MMRM P301 TST ≤9 yr ** p=0.008, * p=0.016, # p=0.074 TNX - 102 SL 5.6 mg group v. placebo, MMRM PTSD Treatment Response to Tonmya in Phase 2 and Phase 3 Studie

  20. Slide 20: Sustained Remission in Phase 2 and Phase 3 Studies

    © 2018 Tonix Pharmaceuticals Holding Corp. 20 Sustained Remission in Phase 2 and Phase 3 Studies: Retrospective Analyses of P201 Entry CAPS - 5 ≥33 and P301 ≤9 Years Since Trauma Subgroups Remission is a clinical state that is essentially asymptomatic In order to confirm remission: • Determined rate

  21. Slide 21: Clinical Evidence of Dose-Effect in Military-Related PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 21 Clinical Evidence (Phase 2) of Dose - Effect in Activity of Tonmya in Military - Related PTSD 1 1 Retrospective analysis of Tonmya 5.6 mg on CAPS - 5 ≥33 (high - moderate) subgroup. in Phase 3, Tonmya 5.6 mg is being studied on a population with a baseli

  22. Slide 22: Retrospective Analyses of Secondary Endpoints in HONOR/P301

    © 2018 Tonix Pharmaceuticals Holding Corp. 22 Retrospective Analyses of ≤9 Years Since Trauma Subgroup on Key Secondary Endpoints in HONOR/P301 Key secondary endpoints showed strong treatment effects • CGI - I, PGIC and PROMIS SD were pre - specified secondary analyses • Support results on CAPS - 5

  23. Slide 23: Adverse Events in AtEase/P201 and HONOR/P301

    © 2018 Tonix Pharmaceuticals Holding Corp. 23 Adverse Events (AEs) in AtEase/P201 and HONOR/P301 No serious and unexpected AEs in P201 or P301 • Systemic AEs comparable between studies and also consistent with those described in approved product labeling • Similar severity and incidence of oral hypo

  24. Slide 24: Time Since Trauma – Review of Published Studies

    © 2018 Tonix Pharmaceuticals Holding Corp. 24 Time Since Trauma – Review of Published Studies Published studies of prazosin suggested effects in military - PTSD prior to 9 years • Loss of treatment effect >9 years Paroxetine and sertraline studies supporting FDA approval were conducted on PTSD > 9 y

  25. Slide 25: Time Since Trauma – Remitting and Persistent Phases of PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 25 Time Since Trauma – Remitting and Persistent Phases of PTSD Kessler et al 1 studied remission in PTSD with and without therapy • Identified remitting and persistent phase of PTSD – with transition at approximately 6 years post trauma • Supported by other

  26. Slide 26: Summary of Clinical Experience with Tonmya in PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 26 Summary of Clinical Experience with Tonmya / TNX - 102 SL in PTSD Median time since trauma (TST) in TNX - 102 SL 5.6 mg group in the HONOR/P301 study (9.5 years) was longer than AtEase/P201 study (6 years) • Both studied military - related PTSD • Time ha

  27. Slide 27: TNX-102 SL – Bedtime Treatment for Multiple Potential Indications

    © 2018 Tonix Pharmaceuticals Holding Corp. 27 TNX - 102 SL – Bedtime Treatment for Multiple Potential Indications Ma nagement of Fibromyalgia (FM) – chronic pain condition • TNX - 102 SL studied at low dose (2.8 mg) – half the dose being developed for PTSD – did not separate from placebo on primary

  28. Slide 28: Agitation in Alzheimer's Disease – Additional Indication

    © 2018 Tonix Pharmaceuticals Holding Corp. 28 Agitation in Alzheimer’s Disease – Additional Indication Being Developed for TNX - 102 SL FDA designated Fast Track development program Significant unmet need • No FDA approved drugs for the treatment of agitation in Alzheimer’s Mechanism of improving sl

  29. Slide 29: TNX-102 SL for Agitation in Alzheimer's – Regulatory Status and Strategy

    © 2018 Tonix Pharmaceuticals Holding Corp. 29 TNX - 102 SL for Agitation in Alzheimer’s – Regulatory Status and Registration Strategy FDA confirmed no additional study is needed prior to IND submission • Pre - IND meeting established open dialogue with the FDA on pivotal clinical study design and ef

  30. Slide 30: Candidates in Development

    © 2018 Tonix Pharmaceuticals Holding Corp. 30 Candidates in Development Preclinical Phase 2 NDA 1 /BLA 2 Market Pipeline Product Indication/ Description Phase 3 Tonmya Bedtime Treatment for PTSD 3 Daytime Treatment for PTSD TNX - 601 Novel polymorph and salt discovered and characterized; Preliminary

  31. Slide 31: TNX-601 (Tianeptine Oxalate): A Potential Clinical Candidate for PTSD

    © 2018 Tonix Pharmaceuticals Holding Corp. 31 TNX - 601 ( Tianeptine Oxalate): A Potential Clinical Candidate for PTSD Pre - IND Candidate Targeted as a 1 st line monotherapy for PTSD: oral formulation for daytime dosing x Leverages expertise in PTSD (clinical and regulatory experience, market analy

  32. Slide 32: TNX-801 (Synthesized Live Horsepox Virus): Smallpox-Preventing Vaccine Candidate

    © 2018 Tonix Pharmaceuticals Holding Corp. 32 TNX - 801 (Synthesized Live Horsepox Virus): A Smallpox - Preventing Vaccine Candidate Pre - IND Stage Potential improvement over current biodefense tools against smallpox ✓ Leverages Tonix’s government affairs effort ✓ Collaboration with Professor David

  33. Slide 33: Management Team

    © 2018 Tonix Pharmaceuticals Holding Corp. 33 Management Team Seth Lederman, MD President & CEO Jessica Morris Chief Operating Officer Gregory Sullivan, MD Chief Medical Officer Bradley Saenger, CPA Chief Financial Officer

  34. Slide 34: Board of Directors

    © 2018 Tonix Pharmaceuticals Holding Corp. 34 Board of Directors Seth Lederman, MD Chairman Adeoye “Oye” Olukotun, MD Squibb, BMS, Mallinckrodt, Esperion John Rhodes Chair, NYS Public Service Commission, CEO, NYS Dept. of Public Service, Booz Allen Charles Mather BTIG, Janney, Jefferies, Cowen, Smit

  35. Slide 35: Milestones – Recently Completed and Upcoming

    © 2018 Tonix Pharmaceuticals Holding Corp. 35 Milestones – Recently Completed and Upcoming □ July 201 8 Completed HONOR/P301 study interim analysis - result did not support study continuation but fine - tuned new Phase 3 study □ August 201 8 Presentation of HONOR/P301 study results at Military Healt

  36. Slide 36: Summary

    © 2018 Tonix Pharmaceuticals Holding Corp. 36 Summary Phase 3 Breakthrough Therapy development for PTSD including military - related PTSD • Major unmet need; ~11 million Americans affected • Potential single - study NDA submission New indication in development for agitation in Alzheimer’s Disease •

  37. Slide 37: Thank you!

    © 2018 Tonix Pharmaceuticals Holding Corp. Thank you ! NASDAQ: TNXP

Tonix Pharmaceuticals Holding — Investor Presentation (October 2018) on 6ix